Back to Interventions
Substance / Medication

Mogamulizumab

SNOMED 773522000UMLS C2987603

Overview

Active Ingredient
mogamulizumab
RxNorm CUI
2054068

Indications

POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.

Labeler: Kyowa Kirin, Inc.Updated: 2025-10-30T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Sézary's disease
Mycosis fungoides (clinical)

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

1 trials linked to this intervention

1
Total Trials
1
Recruiting
0
With Results

Recent Trials

A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy

NCT06285370Phase 4Active Not Recruiting23 enrolled
View all 1 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Clinicopathological definition, management and prognostic value of mogamulizumab-associated rash and other cutaneous events: A systematic review.
Avallone G, Roccuzzo G, Pileri A et al. · J Eur Acad Dermatol Venereol · 2024
PMID: 38279614Meta-Analysis
Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Grimm Sabine E, Witlox Willem, Wolff Robert et al. · Pharmacoeconomics · 2022
PMID: 34664200Meta-AnalysisFull text (PMC)
Safety and efficacy profile of mogamulizumab (Poteligeo) in the treatment of cancers: an update evidence from 14 studies.
Zhang Ting, Sun Jing, Li Jinying et al. · BMC Cancer · 2021
PMID: 34039310Meta-AnalysisFull text (PMC)
Insights into treatment of patients with mycosis fungoides or Sézary syndrome using mogamulizumab.
Foss Francine, Kim Youn H, Scarisbrick Julia et al. · J Dermatolog Treat · 2025
PMID: 39894454RCT
Multicenter, randomized, double-blind, placebo-controlled phase 3 study of mogamulizumab with open-label extension study in a minimum number of patients with human T-cell leukemia virus type-1-associated myelopathy.
Sato Tomoo, Nagai Masahiro, Watanabe Osamu et al. · J Neurol · 2024
PMID: 38430272RCTFull text (PMC)
Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
Horwitz Steven, Zinzani Pier Luigi, Bagot Martine et al. · Leuk Lymphoma · 2021
PMID: 34304674RCTFull text (PMC)
Dermatological adverse events during hematological and oncological therapies (Bruton's tyrosine kinase inhibitors and mogamulizumab): an Italian retrospective multicenter study.
Starace Michela, Cedirian Stephano, Rapparini Luca et al. · Ital J Dermatol Venerol · 2025
PMID: 41041875Observational
Evolution of patients with Sézary syndrome after mogamulizumab discontinuation for any cause except progression: a multicentre retrospective study (Moga-stop Study).
Tzoumpa Sofia, Ingen-Housz-Oro Saskia, de Masson Adèle et al. · Br J Dermatol · 2024
PMID: 38660811Observational
Mogamulizumab-induced bone granuloma: a multicentre nationwide case series.
Amatore Florent, Darbord Delphine, Franck Nathalie et al. · Br J Dermatol · 2023
PMID: 37379572Observational
Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study.
Beylot-Barry M, Quereux G, Nardin C et al. · J Eur Acad Dermatol Venereol · 2023
PMID: 37113040Observational

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Mogamulizumab (substance)
SNOMED CT
773522000
UMLS CUI
C2987603
RxNorm CUI
2054068
Labeler
Kyowa Kirin, Inc.

Clinical Data

This intervention maps to 2 entities in the Ltrl knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
1
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.